Filtered By:
Source: The Lancet Neurology
Condition: Ischemic Stroke
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 88 results found since Jan 2013.
Neurological manifestations of autosomal dominant familial Alzheimer ’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
Publication date: December 2016 Source:The Lancet Neurology, Volume 15, Issue 13 Author(s): Mengxuan Tang, Davis C Ryman, Eric McDade, Mateusz S Jasielec, Virginia D Buckles, Nigel J Cairns, Anne M Fagan, Alison Goate, Daniel S Marcus, Chengjie Xiong, Ricardo F Allegri, Jasmeer P Chhatwal, Adrian Danek, Martin R Farlow, Nick C Fox, Bernardino Ghetti, Neill R Graff-Radford, Christopher Laske, Ralph N Martins, Colin L Masters, Richard P Mayeux, John M Ringman, Martin N Rossor, Stephen P Salloway, Peter R Schofield, John C Morris, Randall J Bateman Background Autosomal dominant familial Alzheimer’s disease (ADAD) is a rare...
Source: The Lancet Neurology - November 7, 2016 Category: Neurology Source Type: research
Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial
Publication date: Available online 23 August 2016 Source:The Lancet Neurology Author(s): Serge Bracard, Xavier Ducrocq, Jean Louis Mas, Marc Soudant, Catherine Oppenheim, Thierry Moulin, Francis Guillemin Background Intravenous thrombolysis with alteplase alone cannot reperfuse most large-artery strokes. We aimed to determine whether mechanical thrombectomy in addition to intravenous thrombolysis improves clinical outcome in patients with acute ischaemic stroke. Methods THRACE is a randomised controlled trial done in 26 centres in France. Patients aged 18–80 years with acute ischaemic stroke and proximal cerebral artery...
Source: The Lancet Neurology - August 23, 2016 Category: Neurology Source Type: research
Intra-arterial therapy for acute ischaemic stroke
Publication date: Available online 23 August 2016 Source:The Lancet Neurology Author(s): Olvert A Berkhemer, Diederik W J Dippel
Source: The Lancet Neurology - August 23, 2016 Category: Neurology Source Type: research
Efficacy and safety of non-immersive virtual reality exercising in stroke rehabilitation (EVREST): a randomised, multicentre, single-blind, controlled trial
Publication date: September 2016 Source:The Lancet Neurology, Volume 15, Issue 10 Author(s): Gustavo Saposnik, Leonardo G Cohen, Muhammad Mamdani, Sepideth Pooyania, Michelle Ploughman, Donna Cheung, Jennifer Shaw, Judith Hall, Peter Nord, Sean Dukelow, Yongchai Nilanont, Felipe De los Rios, Lisandro Olmos, Mindy Levin, Robert Teasell, Ashley Cohen, Kevin Thorpe, Andreas Laupacis, Mark Bayley Background Non-immersive virtual reality is an emerging strategy to enhance motor performance for stroke rehabilitation. There has been rapid adoption of non-immersive virtual reality as a rehabilitation strategy despite the limited ...
Source: The Lancet Neurology - August 8, 2016 Category: Neurology Source Type: research
Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial
We report the effect of intravenous alteplase on long-term survival after ischaemic stroke of participants in the Third International Stroke Trial (IST-3). Methods In IST-3, done at 156 hospitals in 12 countries (Australia, Europe, and the UK), participants (aged >18 years) were randomly assigned with a telephone voice-activated or web-based system in a 1:1 ratio to treatment with intravenous 0·9 mg/kg alteplase plus standard care or standard care alone within 6 h of ischaemic stroke. We followed up participants in the UK and Scandinavia (Sweden and Norway) for survival up to 3 years after randomisation using data...
Source: The Lancet Neurology - July 19, 2016 Category: Neurology Source Type: research
Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study
This study is registered with ClinicalTrials.gov, number NCT02358772. Findings Between Feb 5, 2011, and March 5, 2015, 427 patients were treated within the STEMO vehicle and their data were entered into a pre-hospital registry. 505 patients received conventional care and their data were entered into an in-hospital thrombolysis registry. Of these, 305 patients in the STEMO group and 353 in the conventional care group met inclusion criteria and were included in the analysis. 161 (53%) patients in the STEMO group versus 166 (47%) in the conventional care group had an mRS score of 1 or lower (p=0·14). Compared with conventio...
Source: The Lancet Neurology - July 15, 2016 Category: Neurology Source Type: research
Alteplase in acute ischaemic stroke: no time to slow down
Publication date: Available online 8 June 2016 Source:The Lancet Neurology Author(s): Stefan Kiechl, Johann Willeit
Source: The Lancet Neurology - June 8, 2016 Category: Neurology Source Type: research
Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis
Publication date: Available online 8 June 2016 Source:The Lancet Neurology Author(s): William N Whiteley, Jonathan Emberson, Kennedy R Lees, Lisa Blackwell, Gregory Albers, Erich Bluhmki, Thomas Brott, Geoff Cohen, Stephen Davis, Geoffrey Donnan, James Grotta, George Howard, Markku Kaste, Masatoshi Koga, Rüdiger von Kummer, Maarten G Lansberg, Richard I Lindley, Patrick Lyden, Jean Marc Olivot, Mark Parsons, Danilo Toni, Kazunori Toyoda, Nils Wahlgren, Joanna Wardlaw, Gregory J del Zoppo, Peter Sandercock, Werner Hacke, Colin Baigent Background Randomised trials have shown that alteplase impr...
Source: The Lancet Neurology - June 8, 2016 Category: Neurology Source Type: research
Standardisation of research strategies in acute ischaemic stroke
Publication date: July 2016 Source:The Lancet Neurology, Volume 15, Issue 8 Author(s): Justin F Fraser
Source: The Lancet Neurology - June 6, 2016 Category: Neurology Source Type: research
Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN)
We examined the effect of the baseline Alberta Stroke Program Early CT Score (ASPECTS) on the safety and efficacy of intra-arterial treatment in a subgroup analysis of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN). Methods MR CLEAN was a randomised, controlled, open-label, phase 3 trial of intra-arterial treatment in patients (aged ≥18 years from the Netherlands) with proximal arterial occlusion of the anterior circulation, given intra-arterial treatment within 6 h of stroke onset. The primary outcome was 90 day modified Rankin Scale (mRS) sco...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research
Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation
Publication date: Available online 11 May 2016 Source:The Lancet Neurology Author(s): Ángel Chamorro, Ulrich Dirnagl, Xabier Urra, Anna M Planas Treatments for acute ischaemic stroke continue to evolve after the superior value of endovascular thrombectomy was confirmed over systemic thrombolysis. Unfortunately, numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischaemic stroke, making the search for new treatments imperative. Increased awareness of the relevance of rigorous preclinical testing, and appropriate selection of study participants, might overcome the barriers to progress...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research
Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial
Publication date: May 2016 Source:The Lancet Neurology, Volume 15, Issue 6 Author(s): Thorsten Steiner, Sven Poli, Martin Griebe, Johannes Hüsing, Jacek Hajda, Anja Freiberger, Martin Bendszus, Julian Bösel, Hanne Christensen, Christian Dohmen, Michael Hennerici, Jennifer Kollmer, Henning Stetefeld, Katja E Wartenberg, Christian Weimar, Werner Hacke, Roland Veltkamp Background Haematoma expansion is a major cause of mortality in intracranial haemorrhage related to vitamin K antagonists (VKA-ICH). Normalisation of the international normalised ratio (INR) is recommended, but optimum haemostatic managemen...
Source: The Lancet Neurology - April 19, 2016 Category: Neurology Source Type: research
Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies
Publication date: Available online 7 April 2016 Source:The Lancet Neurology Author(s): Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) ConsortiumStroke Genetics Network (SiGN)International Stroke Genetics Consortium (ISGC) Background Genetic determinants of stroke, the leading neurological cause of death and disability, are poorly understood and have seldom been explored in the general population. Our aim was to identify additional loci for stroke by doing a meta-analysis of genome-wide association studies. Methods For the discovery sample, we did a genome-wide analys...
Source: The Lancet Neurology - April 7, 2016 Category: Neurology Source Type: research
Human genetics shines a light on ischaemic stroke
Publication date: Available online 19 December 2015 Source:The Lancet Neurology Author(s): Benjamin F Voight, Daniel J Rader
Source: The Lancet Neurology - December 19, 2015 Category: Neurology Source Type: research
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study
Publication date: Available online 19 December 2015 Source:The Lancet Neurology Author(s): NINDS Stroke Genetics Network (SiGN)International Stroke Genetics Consortium (ISGC) Background The discovery of disease-associated loci through genome-wide association studies (GWAS) is the leading genetic approach to the identification of novel biological pathways underlying diseases in humans. Until recently, GWAS in ischaemic stroke have been limited by small sample sizes and have yielded few loci associated with ischaemic stroke. We did a large-scale GWAS to identify additional susceptibility genes for stroke and its subtypes. ...
Source: The Lancet Neurology - December 19, 2015 Category: Neurology Source Type: research
